Medigene's drug Veregen® Receives Marketing Authorization in Israel, Denmark and Slovakia
(Thomson Reuters ONE) -
MediGene AG /
Medigene's drug Veregen® Receives Marketing Authorization in Israel, Denmark and
Slovakia
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, August 1, 2012. Medigene AG (MDG, Frankfurt, Prime Standard)
announced today that Veregen(® )for the treatment of genital warts has obtained
marketing authorization in Israel, Denmark and Slovakia. Market launch of
Veregen(®) in Denmark, Norway and Sweden by Medigene's partner Azanta is
expected early 2013 and market launch in Israel, by Medigene's partner Teva, is
expected during 2013.
Veregen(®) is already being marketed successfully in the USA (by Fougera),
Germany and Austria (by Abbott), and Spain (by Bial). Marketing authorizations
in additional countries are granted or expected within the next few months.
Medigene has entered into several marketing partnerships for Veregen(®) across
Europe, Asia, and America and is planning to continue this global licensing
strategy.
Veregen(®): Veregen(®) (previously Polyphenon E(®) ointment), a topical
treatment for external genital warts, contains a concentrate of catechins with a
complex defined composition extracted from green tea leaves. Medigene acquired
the rights to the active ingredient in Veregen(®) from Epitome Pharmaceuticals,
Inc. in 1999 and was solely responsible for the drug's successful preclinical
and clinical development, as well as the approval process. Sinecatechins 15%
ointment (Veregen(®)) is recommended as a possible option for treating genital
warts in the US Department of Health and Human Services Center for Disease
Control and Prevention's Sexually Transmitted Diseases Treatment Guidelines
2010.
Medigene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials and is developing an innovative vaccine
technology. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of Medigene AG. Polyphenon
E(® )is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
- End -
Contact
Julia Hofmann & Kerstin Langlotz
Tel.: +49 - 89 - 20 00 33 - 33 01
Fax: +49 - 89 - 20 00 33 - 29 20
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as pdf:
http://hugin.info/132073/R/1631018/522797.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MediGene AG via Thomson Reuters ONE
[HUG#1631018]
Unternehmensinformation / Kurzprofil:
Datum: 01.08.2012 - 08:30 Uhr
Sprache: Deutsch
News-ID 170545
Anzahl Zeichen: 4151
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 286 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene's drug Veregen® Receives Marketing Authorization in Israel, Denmark and Slovakia"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
